This study focuses on individuals with Idiopathic Pulmonary Fibrosis, a condition where the lungs become scarred and thickened over time, making it harder to breathe. The goal of the study is to evaluate the safety and effectiveness of a new investigational medicine called ABBV-142. This treatment is a humanised igg1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1, which is a type of protein-based medicine designed to target specific processes in the body. ABBV-142 will be given to participants through intravenous administration, meaning it is delivered directly into a vein as a solution for injection/infusion.

During the study, some participants will receive the active medicine, while others will receive a placebo. The research involves monitoring how the medicine affects the body over a period of time to see if it can change the way the disease progresses. The course of the study includes regular check-ups to observe any changes in health or how the lungs are functioning.